HOME >> MEDICINE >> NEWS
Targeted therapy shows significant benefits over standard treatment for advanced kidney cancer

ATLANTA According to a new study, the drug sunitinib malate (Sutent) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.

"This drug has shown more activity as a single agent against advanced kidney cancer than any other drug I've studied in the past 15 years," said the study's lead author Robert J. Motzer, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). "I continue to be encouraged by its effectiveness in treating patients with this aggressive disease," said Dr. Motzer, who is a leader in the treatment of kidney cancer and conducted the earliest clinical trials on sunitinib (initially referred to as SU11248).

Interferon-alpha (IFN-) is one of the standard treatments for advanced kidney cancer, however only about 15 percent of patients respond to this immunotherapy. Sunitinib targets receptors on kidney cancer cells that may play a role in tumor growth and the development of blood vessels that feed a tumor. Previous clinical trials, also led by Dr. Motzer, showed that sunitinib caused some renal cell cancers to shrink, but this study is the first to demonstrate its effectiveness as a first-line therapy compared with standard cytokine therapy with IFN-.

The current randomized trial included 750 patients over the age of 60, half of whom were treated with a six-week cycle of sunitinib and half of whom were treated with a six-week cycle of the current treatment standard, IFN-. The primary endpoint of the trial was a comparison of progression-free survival between sunitinib and IFN- as assessed by independent third-party review. The median progression-free survival for treatment with sunitinib was 11 months, compared with 5 months following treatment with IFN-. This outcome was statistical
'"/>

Contact: Maria Connizzo
mediastaff@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
4-Jun-2006


Page: 1 2

Related medicine news :

1. Targeted, oral agent Enzastaurin shows favorable results
2. Targeted initiatives can encourage people to walk more
3. Targeted nanoparticles incorporating siRNA offer promise for cancer treatment
4. Targeted cancer drugs may work by disrupting balance of cellular signals
5. Targeted melanoma education of high risk groups improves screening
6. Targeted lymph node examination improves staging of colon cancer
7. Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
8. Chemotherapy with bevacizumab increases risk of blood clots in arteries
9. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
10. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
11. Hormone therapy offers new hope for ovarian cancer patients

Post Your Comments:
(Date:7/31/2014)... have learned that recent fears of invasive lionfish causing ... to control lionfish by fishing derbies and targeted fisheries ... And there,s a simple way to know for sure ... it,s been cooked. , Pacific lionfish were first reported ... have been gaining swiftly in number ever since. They,re ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Setting goals for ... on blogs on successful tips to weight loss. Fitness on ... for over 8 years, and has worked with 6000 customers ... “We have had the chance to monitor why customers start ... exercising, how long they stick to their program, whether or ...
(Date:7/31/2014)... July 31, 2014 Millions of people ... have had traumatic experiences as a child and some ... work. As a highly experienced NJ cosmetic dentist, ... anxiety during their dental procedure. To help these ... team at Champagne Smiles offer several sedation dentistry techniques. ...
(Date:7/31/2014)... Cape Coral, FL (PRWEB) July 31, 2014 ... the opportunity to take charge of their financial future. ... training for women, has opened registration for 6 upcoming ... designed by women, for women, and with input from ... (Rich Woman and It’s Rising Time) who is passionate ...
(Date:7/31/2014)... July 31, 2014 Dr. Andrew Lian-Jie ... Board of Dermatology, fellowship trained Mohs surgeon that has ... Docs. , After extensive dermatology research training at the ... Dr. Li completed his internship in internal medicine at ... of Pennsylvania in Philadelphia. Dr. Li pursued further training ...
Breaking Medicine News(10 mins):Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:Champagne Smiles is Thrilled to Now Offer Sedation Dentistry to their Patients 2Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2
(Date:7/31/2014)... , July 31, 2014 Touro University ... has been selected as the recipient of a $150,000 ... will allow the University to increase research and classroom ... creating state-of-the-art technology for the study of health sciences, ... the diverse needs and interests of our students," said ...
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... ANTWERP, Belgium and LONDON , July ... Organization (CRO) and services provider for the medical industries, announced today ... The United Kingdom has one ... valued at USD 8.9 billion in 2012 and it is projected ... was estimated at USD 234 billion in 2012, equal to 9.5% ...
Breaking Medicine Technology:Touro University California Garners Grant From Long Foundation 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2genae Opens Offices in London 2
Cached News: